[Extracorporeal immunopharmacological therapy in the treatment of patients with acutely progressing froms of pulmonary tuberculosis].
Extracorporeal immune-pharmacological therapy, involving Diuciphonium, was added to the complex treatment of 46 patients primarily diagnosed as having acutely progressing destructive pulmonary tuberculosis. Investigations showed that this method sped up the regression of clinical and X-ray signs, during 1 to 2 months, and recovered the immune reactivity in 89% of patients. The clinical changes were dynamically compared with those of 50 other patients in another group (including 39 patients with caseous pneumonia), who were treated by small-volume plasmapheresis. Advantages of applying the extracorporeal immune-pharmacological therapy were demonstrated; they comprise: a shorter time needed to arrest the endotoxicosis, a fuller and faster recovery of the main populations and sub-populations of lymphocytes and a less number of fatal outcomes.
Chelnokova
O G
OG
Kibrik
B S
BS
D000208:Acute Disease; D000975:Antioxidants / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology*; D015704:CD4 Antigens / Q000276:immunology*; D018450:Disease Progression; D006684:HLA-DR Antigens / Q000276:immunology*; D006801:Humans; D010956:Plasmapheresis / Q000379:methods; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology*
D000975:Antioxidants; D001993:Bronchodilator Agents; D017252:CD3 Complex; D015704:CD4 Antigens; D006684:HLA-DR Antigens; D015375:Receptors, Interleukin-2